IL164440A0 - New pharmaceutical composition containing fibanserin polymorph a - Google Patents
New pharmaceutical composition containing fibanserin polymorph aInfo
- Publication number
- IL164440A0 IL164440A0 IL16444004A IL16444004A IL164440A0 IL 164440 A0 IL164440 A0 IL 164440A0 IL 16444004 A IL16444004 A IL 16444004A IL 16444004 A IL16444004 A IL 16444004A IL 164440 A0 IL164440 A0 IL 164440A0
- Authority
- IL
- Israel
- Prior art keywords
- polymorph
- fibanserin
- pharmaceutical composition
- composition containing
- new pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002053 flibanserin Drugs 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02011224 | 2002-05-22 | ||
| PCT/EP2003/005226 WO2003097058A1 (en) | 2002-05-22 | 2003-05-19 | New pharmaceutical compositions containing flibanserin polymorph a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164440A0 true IL164440A0 (en) | 2005-12-18 |
Family
ID=29433081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16444004A IL164440A0 (en) | 2002-05-22 | 2004-10-05 | New pharmaceutical composition containing fibanserin polymorph a |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1511489B1 (zh) |
| JP (1) | JP3919788B2 (zh) |
| KR (1) | KR101054237B1 (zh) |
| CN (3) | CN1655789A (zh) |
| AT (1) | ATE499939T1 (zh) |
| BR (1) | BRPI0311189B8 (zh) |
| CA (1) | CA2483597C (zh) |
| CY (1) | CY1111470T1 (zh) |
| DE (1) | DE60336225D1 (zh) |
| DK (1) | DK1511489T3 (zh) |
| EA (1) | EA007185B1 (zh) |
| EC (1) | ECSP045493A (zh) |
| ES (1) | ES2361994T3 (zh) |
| HR (1) | HRP20041092B1 (zh) |
| IL (1) | IL164440A0 (zh) |
| ME (1) | MEP55308A (zh) |
| MX (1) | MXPA04011487A (zh) |
| NO (1) | NO329414B1 (zh) |
| NZ (1) | NZ537253A (zh) |
| PL (1) | PL211062B1 (zh) |
| RS (1) | RS51718B (zh) |
| SI (1) | SI1511489T1 (zh) |
| UA (1) | UA80135C2 (zh) |
| WO (1) | WO2003097058A1 (zh) |
| ZA (1) | ZA200408151B (zh) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
| UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
| WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| WO2006125042A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of drug-induced sexual dysfunction |
| CA2608713A1 (en) * | 2005-05-19 | 2006-11-23 | Boehringer Ingelheim International Gmbh | Method for the treatment of sexual dysfunctions due to medical conditions |
| JP2009503020A (ja) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 肥満症の治療におけるフリバンセリンの使用 |
| JP2009513604A (ja) | 2005-10-29 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体 |
| US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
| EP2037927B1 (en) | 2006-06-30 | 2010-01-27 | Boehringer Ingelheim International GmbH | Flibanserin for the treatment of urinary incontinence and related diseases |
| JP5793828B2 (ja) | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フリバンセリンの製剤及びその製造方法 |
| CL2007002214A1 (es) | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
| EP2056797A2 (en) | 2006-08-25 | 2009-05-13 | Boehringer Ingelheim International GmbH | Controlled release system and method for manufacturing the same |
| CA2672957C (en) | 2006-12-20 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity |
| EP1955699A1 (en) * | 2007-02-08 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flibanserin for the treatment of insomnia |
| UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
| EP2090297A1 (en) * | 2008-02-13 | 2009-08-19 | Boehringer Ingelheim International GmbH | Formulations of flibanserin |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
| CN104926734B (zh) * | 2015-07-07 | 2017-04-05 | 苏州立新制药有限公司 | 氟班色林的制备方法 |
| US11492343B2 (en) | 2016-01-31 | 2022-11-08 | Xiaoming Meng | Polymorph of flibanserin and preparation method thereof and use of same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| AU2002331361B2 (en) * | 2001-08-02 | 2008-06-05 | Sprout Pharmaceuticals, Inc. | Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
| DE10138273A1 (de) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Arzneimittel mit neuroprotektiver Wirkung |
-
2003
- 2003-05-19 BR BRPI0311189A patent/BRPI0311189B8/pt not_active IP Right Cessation
- 2003-05-19 CA CA2483597A patent/CA2483597C/en not_active Expired - Fee Related
- 2003-05-19 ME MEP-553/08A patent/MEP55308A/xx unknown
- 2003-05-19 CN CNA038117029A patent/CN1655789A/zh active Pending
- 2003-05-19 ES ES03730069T patent/ES2361994T3/es not_active Expired - Lifetime
- 2003-05-19 CN CNA2007100014771A patent/CN101002780A/zh active Pending
- 2003-05-19 WO PCT/EP2003/005226 patent/WO2003097058A1/en active Application Filing
- 2003-05-19 DE DE60336225T patent/DE60336225D1/de not_active Expired - Lifetime
- 2003-05-19 SI SI200331994T patent/SI1511489T1/sl unknown
- 2003-05-19 UA UA20041210555A patent/UA80135C2/uk unknown
- 2003-05-19 EP EP03730069A patent/EP1511489B1/en not_active Expired - Lifetime
- 2003-05-19 DK DK03730069.6T patent/DK1511489T3/da active
- 2003-05-19 EA EA200401515A patent/EA007185B1/ru not_active IP Right Cessation
- 2003-05-19 CN CN201110122058XA patent/CN102240289A/zh active Pending
- 2003-05-19 JP JP2004505057A patent/JP3919788B2/ja not_active Expired - Fee Related
- 2003-05-19 KR KR1020047018741A patent/KR101054237B1/ko active IP Right Grant
- 2003-05-19 MX MXPA04011487A patent/MXPA04011487A/es active IP Right Grant
- 2003-05-19 PL PL372457A patent/PL211062B1/pl unknown
- 2003-05-19 NZ NZ537253A patent/NZ537253A/en not_active IP Right Cessation
- 2003-05-19 AT AT03730069T patent/ATE499939T1/de active
- 2003-05-19 RS YU98704A patent/RS51718B/en unknown
-
2004
- 2004-10-05 IL IL16444004A patent/IL164440A0/xx unknown
- 2004-10-08 ZA ZA200408151A patent/ZA200408151B/en unknown
- 2004-10-22 NO NO20044547A patent/NO329414B1/no not_active IP Right Cessation
- 2004-11-19 HR HRP20041092AA patent/HRP20041092B1/hr not_active IP Right Cessation
- 2004-12-13 EC EC2004005493A patent/ECSP045493A/es unknown
-
2011
- 2011-05-17 CY CY20111100475T patent/CY1111470T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111470T1 (el) | Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α | |
| TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| UA96449C2 (en) | Stable laquinimod preparations | |
| HK1076605A1 (en) | Formulations | |
| TW200505875A (en) | Novel compounds | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| WO2004093800A3 (en) | Thyronamine derivatives and analogs and methods of use thereof | |
| NO20064808L (no) | Orale matrixformuleringer med licarbazepin | |
| TW200509992A (en) | Dosage form containing pantoprazole as active ingredient | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| MY142076A (en) | Emulsifying systems containing azetidine derivatives | |
| UA87152C2 (ru) | Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения | |
| TNSN06013A1 (en) | Semi-solid systems containing azetidine derivatives | |
| TW200503783A (en) | Oral pharmaceutical preparation for proton pump antagonists | |
| TW200633717A (en) | Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents | |
| AU2003284786A8 (en) | Microemulsion composition for oral administration of biphenyldimethyldicarboxylate | |
| TNSN08242A1 (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. | |
| WO2001095890A3 (en) | Oral pharmaceutical compositions containing terbinafine | |
| TNSN06299A1 (en) | Oral matrix formulations comprising licarbazepine | |
| IL162857A0 (en) | Oral vaccination | |
| MD20040296A (ro) | Compoziţie farmaceutică, conţinând oxcarbazepină cu eliberare prelungită a ingredientului activ |